RLAY Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.32%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $143,028.93

Relay Therapeutics Insider Trading History Chart

Relay Therapeutics Share Price & Price History

^$6.51

▼ -0.23 (-3.41%)

As of 05/8/2024 01:00 AM ET

Days: 30 | 90 | 365

BREAKING – Pentagon to Spend $20 Billion on “Distributed AI”

From Behind the Markets | Ad

BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.

Discover the name and ticker of this $2 stock here >>>

Relay Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/29/2024	Peter Rahmer	Insider	Sell	1,345	$6.38	$8,581.10	513,334
4/29/2024	Thomas Catinazzo	CFO	Sell	1,695	$6.38	$10,814.10	339,803
3/27/2024	Donald A. Bergstrom	Insider	Sell	765	$7.70	$5,890.50	530,113
3/27/2024	Thomas Catinazzo	CFO	Sell	348	$7.70	$2,679.60	341,498
1/29/2024	Peter Rahmer	Insider	Sell	1,651	$9.64	$15,915.64	514,977
1/29/2024	Thomas Catinazzo	CFO	Sell	2,005	$9.64	$19,328.20	341,846
12/27/2023	Peter Rahmer	Insider	Sell	244	$11.51	$2,808.44	316,628
12/27/2023	Thomas Catinazzo	CFO	Sell	294	$11.51	$3,383.94	143,851
10/30/2023	Peter Rahmer	Insider	Sell	1,354	$6.03	$8,164.62	316,872
10/30/2023	Thomas Catinazzo	CFO	Sell	1,697	$6.03	$10,232.91	144,145
9/27/2023	Donald A. Bergstrom	Insider	Sell	648	$8.38	$5,430.24	238,484
9/27/2023	Thomas Catinazzo	CFO	Sell	294	$8.38	$2,463.72	145,842
7/28/2023	Peter Rahmer	Insider	Sell	1,352	$11.80	$15,953.60	316,808
7/28/2023	Thomas Catinazzo	CFO	Sell	1,693	$11.80	$19,977.40	146,136
6/27/2023	Donald A. Bergstrom	Insider	Sell	647	$12.12	$7,841.64	240,587
6/27/2023	Thomas Catinazzo	CFO	Sell	294	$12.12	$3,563.28	147,829
4/28/2023	Peter Rahmer	Insider	Sell	739	$11.16	$8,247.24	157,504
4/28/2023	Thomas Catinazzo	CFO	Sell	863	$11.16	$9,631.08	149,272
3/27/2023	Peter Rahmer	Insider	Sell	297	$15.36	$4,561.92	158,243
3/27/2023	Thomas Catinazzo	CFO	Sell	347	$15.36	$5,329.92	150,135
2/8/2023	Sanjiv Patel	CEO	Sell	14,000	$20.98	$293,720.00
1/30/2023	Peter Rahmer	Insider	Sell	740	$21.56	$15,954.40	158,540
1/30/2023	Thomas Catinazzo	CFO	Sell	864	$21.56	$18,627.84	150,482
1/18/2023	Sanjiv Patel	CEO	Sell	28,000	$20.87	$584,360.00	254,554
1/12/2023	Brian Adams	Insider	Sell	9,994	$20.00	$199,880.00	51,531
12/27/2022	Donald A. Bergstrom	Insider	Sell	980	$14.49	$14,200.20	85,886
12/27/2022	Thomas Catinazzo	CFO	Sell	445	$14.49	$6,448.05	50,231
11/10/2022	Sanjiv Patel	CEO	Sell	28,000	$20.00	$560,000.00	254,554
11/8/2022	Sanjiv Patel	CEO	Sell	14,000	$20.18	$282,520.00	254,554
11/1/2022	Donald A. Bergstrom	Insider	Sell	8,000	$22.75	$182,000.00	86,866
10/28/2022	Andy Porter	Insider	Sell	448	$21.54	$9,649.92	45,164
10/28/2022	Thomas Catinazzo	CFO	Sell	1,099	$21.54	$23,672.46	50,676
10/12/2022	Sanjiv Patel	CEO	Sell	14,000	$21.18	$296,520.00	254,554
10/3/2022	Donald A. Bergstrom	Insider	Sell	8,000	$22.43	$179,440.00	88,683
9/27/2022	Brian Adams	Insider	Sell	294	$22.73	$6,682.62	62,548
9/27/2022	Thomas Catinazzo	CFO	Sell	443	$22.73	$10,069.39	51,775
9/14/2022	Sanjiv Patel	CEO	Sell	14,000	$23.47	$328,580.00	254,554
9/8/2022	Mark Murcko	Director	Sell	25,000	$29.95	$748,750.00	996,952
9/8/2022	Thomas Catinazzo	CFO	Sell	26,257	$30.00	$787,710.00	52,218
8/24/2022	Donald A. Bergstrom	Insider	Sell	15,000	$25.00	$375,000.00	89,659
8/5/2022	Donald A. Bergstrom	Insider	Sell	8,000	$20.00	$160,000.00	89,659
7/28/2022	Andy Porter	Insider	Sell	452	$21.27	$9,614.04	45,871
7/28/2022	Thomas Catinazzo	CFO	Sell	734	$21.26	$15,604.84	52,218
7/6/2022	Donald A. Bergstrom	Insider	Sell	8,000	$20.00	$160,000.00	91,494
6/27/2022	Andy Porter	Insider	Sell	265	$20.31	$5,382.15	46,323
6/27/2022	Thomas Catinazzo	CFO	Sell	300	$20.31	$6,093.00	52,952
6/24/2022	Donald A. Bergstrom	Insider	Sell	8,000	$20.00	$160,000.00	92,493
5/2/2022	Donald A. Bergstrom	Insider	Sell	13,000	$24.62	$320,060.00	92,493
4/28/2022	Donald A. Bergstrom	Insider	Sell	1,811	$25.57	$46,307.27	92,493
4/28/2022	Thomas Catinazzo	CFO	Sell	725	$25.57	$18,538.25	53,252
4/13/2022	Sanjiv Patel	CEO	Sell	28,000	$31.95	$894,600.00	253,740
4/1/2022	Donald A. Bergstrom	Insider	Sell	18,000	$30.32	$545,760.00	94,304
3/29/2022	Andy Porter	Insider	Sell	294	$29.87	$8,781.78
3/29/2022	Thomas Catinazzo	CFO	Sell	282	$29.87	$8,423.34
3/24/2022	Donald A. Bergstrom	Insider	Sell	10,000	$30.00	$300,000.00
3/24/2022	Thomas Catinazzo	CFO	Sell	13,286	$30.00	$398,580.00
3/10/2022	Donald A. Bergstrom	Insider	Sell	10,000	$25.00	$250,000.00
3/1/2022	Donald A. Bergstrom	Insider	Sell	8,000	$23.88	$191,040.00
2/22/2022	Donald A. Bergstrom	Insider	Sell	22,994	$20.94	$481,494.36
12/27/2021	Andy Porter	Insider	Sell	260	$33.10	$8,606.00
12/27/2021	Thomas Catinazzo	SVP	Sell	295	$33.10	$9,764.50
11/15/2021	Brian Adams	General Counsel	Sell	6,500	$35.42	$230,230.00
11/15/2021	Thomas Catinazzo	SVP	Sell	22,500	$35.40	$796,500.00
10/15/2021	Donald A. Bergstrom	Insider	Sell	30,000	$34.15	$1,024,500.00
9/27/2021	Donald A. Bergstrom	Insider	Sell	646	$36.87	$23,818.02
9/27/2021	Thomas Catinazzo	SVP	Sell	293	$36.87	$10,802.91
9/13/2021	Brian Adams	General Counsel	Sell	6,500	$35.02	$227,630.00	32,077
9/13/2021	Thomas Catinazzo	SVP	Sell	22,500	$35.00	$787,500.00	38,077
6/16/2021	Donald A. Bergstrom	Insider	Sell	42,242	$33.75	$1,425,667.50	119,483
6/7/2021	Brian Adams	General Counsel	Sell	6,500	$35.00	$227,500.00	32,370
6/7/2021	Thomas Catinazzo	SVP	Sell	22,500	$35.00	$787,500.00	38,370

The Best AI Stock to Own in the World Today is Trading for Just $25

From Banyan Hill Publishing | Ad

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

SEC Filings (Institutional Ownership Changes) for Relay Therapeutics (NASDAQ:RLAY)

96.98% of Relay Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Relay Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/8/2024	ProShare Advisors LLC	26,214	$0.22M	0.0%	+14.9%	0.020%
5/8/2024	Russell Investments Group Ltd.	179,972	$1.49M	0.0%	+57.2%	0.136%
5/7/2024	Susquehanna Fundamental Investments LLC	15,325	$0.13M	0.0%	N/A	0.012%
5/7/2024	Susquehanna Portfolio Strategies LLC	208,356	$1.73M	0.0%	-0.8%	0.157%
5/7/2024	Swiss National Bank	163,500	$1.36M	0.0%	+4.5%	0.123%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	54,917	$0.46M	0.0%	+7.2%	0.041%
5/1/2024	Baillie Gifford & Co.	353,226	$2.93M	0.0%	-5.5%	0.267%
4/30/2024	Allspring Global Investments Holdings LLC	9,569	$79K	0.0%	N/A	0.007%
4/29/2024	Principal Financial Group Inc.	25,775	$0.21M	0.0%	-6.8%	0.019%
4/29/2024	China Universal Asset Management Co. Ltd.	25,210	$0.21M	0.0%	+76.8%	0.019%
4/26/2024	Mesirow Financial Investment Management Inc.	17,627	$0.15M	0.0%	N/A	0.013%
4/19/2024	Mesirow Financial Investment Management Inc.	17,627	$0.15M	0.7%	N/A	0.013%
4/18/2024	Allspring Global Investments Holdings LLC	9,569	$79K	0.0%	N/A	0.007%
4/15/2024	TrueMark Investments LLC	54,445	$0.45M	0.4%	+13.5%	0.042%
4/11/2024	Congress Asset Management Co. MA	149,082	$1.24M	0.0%	+1.4%	0.114%
4/5/2024	Los Angeles Capital Management LLC	13,939	$0.12M	0.0%	+25.7%	0.011%
3/11/2024	Vanguard Group Inc.	10,650,387	$117.26M	0.0%	+0.9%	8.119%
2/15/2024	BVF Inc. IL	3,970,045	$43.71M	1.1%	+67.8%	3.115%
2/14/2024	Caxton Associates LP	279,101	$3.07M	0.2%	+637.3%	0.219%
2/14/2024	Pennant Investors LP	42,400	$0.47M	0.1%	N/A	0.033%
2/14/2024	Bellevue Group AG	5,936,082	$65.36M	1.0%	+21.5%	4.657%
2/13/2024	Affinity Asset Advisors LLC	300,000	$3.30M	0.6%	N/A	0.235%
2/13/2024	Rafferty Asset Management LLC	327,548	$3.61M	0.0%	-13.3%	0.257%
2/13/2024	Rhenman & Partners Asset Management AB	390,000	$4.29M	0.4%	+105.3%	0.306%
2/13/2024	NEOS Investment Management LLC	22,110	$0.24M	0.0%	N/A	0.017%
2/13/2024	Finepoint Capital LP	1,317,870	$14.51M	4.1%	+51.3%	1.034%
2/12/2024	TD Asset Management Inc	467,966	$5.15M	0.0%	-5.9%	0.367%
2/9/2024	Quest Partners LLC	13,380	$0.15M	0.0%	N/A	0.010%
2/9/2024	Trexquant Investment LP	128,890	$1.42M	0.0%	-35.1%	0.101%
2/9/2024	Dynamic Technology Lab Private Ltd	20,763	$0.23M	0.0%	+41.8%	0.016%
2/9/2024	Norges Bank	3,068,973	$33.79M	0.0%	N/A	2.408%
2/7/2024	Teacher Retirement System of Texas	18,357	$0.20M	0.0%	-18.2%	0.014%
2/7/2024	E Fund Management Co. Ltd.	17,486	$0.19M	0.0%	-9.9%	0.014%
2/6/2024	Charles Schwab Investment Management Inc.	877,813	$9.67M	0.0%	+22.8%	0.689%
2/6/2024	M&T Bank Corp	54,285	$0.60M	0.0%	+18.0%	0.043%
2/6/2024	Swiss National Bank	156,400	$1.72M	0.0%	-10.0%	0.123%
2/5/2024	Victory Capital Management Inc.	11,467	$0.13M	0.0%	N/A	0.009%
2/5/2024	Russell Investments Group Ltd.	114,488	$1.26M	0.0%	+1,766.8%	0.090%
2/1/2024	New York State Common Retirement Fund	36,678	$0.40M	0.0%	+3.2%	0.029%
2/1/2024	Handelsbanken Fonder AB	29,500	$0.33M	0.0%	+5.7%	0.023%
1/26/2024	Baillie Gifford & Co.	373,596	$4.11M	0.0%	-5.3%	0.293%
1/24/2024	DekaBank Deutsche Girozentrale	68,937	$0.76M	0.0%	+14.9%	0.054%
1/24/2024	China Universal Asset Management Co. Ltd.	14,257	$0.16M	0.0%	+354.8%	0.011%
1/16/2024	Raymond James Financial Services Advisors Inc.	58,353	$0.64M	0.0%	-2.8%	0.046%
1/16/2024	Raymond James & Associates	18,406	$0.20M	0.0%	-11.5%	0.014%
1/12/2024	SG Americas Securities LLC	91,973	$1.01M	0.0%	+139.4%	0.075%
1/11/2024	TrueMark Investments LLC	47,958	$0.53M	0.5%	N/A	0.039%
1/8/2024	Harbor Capital Advisors Inc.	38,064	$0.42M	0.1%	-7.6%	0.031%
1/5/2024	Exchange Traded Concepts LLC	14,962	$0.17M	0.0%	+34.0%	0.012%
12/18/2023	Vanguard Group Inc.	10,552,362	$88.75M	0.0%	+0.2%	8.560%
11/15/2023	GSA Capital Partners LLP	112,101	$0.94M	0.1%	+88.8%	0.091%
11/14/2023	MPM Bioimpact LLC	1,352,133	$11.37M	3.0%	-0.2%	1.097%
11/14/2023	Corton Capital Inc.	39,402	$0.33M	0.2%	+20.6%	0.032%
11/14/2023	Caxton Associates LP	37,854	$0.32M	0.0%	N/A	0.031%
11/14/2023	Trexquant Investment LP	198,671	$1.67M	0.0%	+926.5%	0.161%
11/14/2023	Profund Advisors LLC	63,931	$0.54M	0.0%	-43.5%	0.052%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	39,202	$0.33M	0.0%	N/A	0.032%
11/13/2023	Algert Global LLC	200,823	$1.69M	0.1%	+61.6%	0.163%
11/13/2023	Healthcare of Ontario Pension Plan Trust Fund	98,000	$0.82M	0.0%	+34.6%	0.080%
11/13/2023	Aigen Investment Management LP	16,828	$0.14M	0.0%	N/A	0.014%
11/13/2023	FMR LLC	2,107,733	$17.73M	0.0%	-28.7%	1.710%
11/13/2023	Rafferty Asset Management LLC	377,745	$3.18M	0.0%	-39.8%	0.306%
11/13/2023	Baillie Gifford & Co.	394,450	$3.32M	0.0%	-4.1%	0.320%
11/13/2023	E Fund Management Co. Ltd.	19,403	$0.16M	0.0%	-42.4%	0.016%
11/9/2023	Deutsche Bank AG	51,779	$0.44M	0.0%	+13.4%	0.042%
11/9/2023	Citigroup Inc.	171,084	$1.44M	0.0%	-15.2%	0.139%
11/9/2023	Skandinaviska Enskilda Banken AB publ	7,900	$66K	0.0%	-16.8%	0.006%
11/8/2023	HighTower Advisors LLC	285,343	$2.40M	0.0%	N/A	0.234%
11/8/2023	Charles Schwab Investment Management Inc.	714,805	$6.01M	0.0%	+6.3%	0.585%
11/8/2023	Swiss National Bank	173,800	$1.46M	0.0%	+1.2%	0.142%
11/7/2023	Quantbot Technologies LP	23,200	$0.20M	0.0%	N/A	0.019%
11/7/2023	Barclays PLC	215,469	$1.81M	0.0%	-30.3%	0.176%
11/7/2023	Jump Financial LLC	103,194	$0.87M	0.0%	-11.4%	0.084%
11/2/2023	Principal Financial Group Inc.	30,464	$0.26M	0.0%	+17.4%	0.025%
11/2/2023	M&T Bank Corp	46,013	$0.39M	0.0%	+46.7%	0.038%
10/27/2023	TD Asset Management Inc	497,490	$4.18M	0.0%	+88.8%	0.407%
10/26/2023	Mirae Asset Global Investments Co. Ltd.	52,019	$0.44M	0.0%	-15.0%	0.043%
10/25/2023	Zurcher Kantonalbank Zurich Cantonalbank	19,165	$0.16M	0.0%	+37.5%	0.016%
10/25/2023	Intellectus Partners LLC	50,560	$0.43M	0.1%	+4.1%	0.041%
10/24/2023	Raymond James & Associates	20,805	$0.18M	0.0%	-41.6%	0.017%
10/13/2023	SG Americas Securities LLC	38,414	$0.32M	0.0%	N/A	0.031%
8/15/2023	Boxer Capital LLC	1,819,132	$22.85M	1.1%	-16.1%	1.490%
8/15/2023	Capital Impact Advisors LLC	24,117	$0.30M	0.3%	+6.7%	0.020%
8/14/2023	NinePointTwo Capital LLC	22,907	$0.29M	0.1%	N/A	0.019%
8/14/2023	Casdin Capital LLC	5,998,574	$75.34M	6.6%	+5.3%	4.911%
8/14/2023	ArrowMark Colorado Holdings LLC	3,418,669	$42.94M	0.5%	+28.0%	2.799%
8/14/2023	Bellevue Group AG	4,170,800	$52.39M	0.7%	0.0%	3.415%
8/14/2023	Jefferies Financial Group Inc.	434,209	$5.45M	0.0%	+302.4%	0.356%
8/14/2023	Driehaus Capital Management LLC	593,002	$7.45M	0.1%	-62.5%	0.486%
8/11/2023	Schroder Investment Management Group	220,482	$2.77M	0.0%	-17.8%	0.181%
8/11/2023	Artal Group S.A.	1,213,725	$15.24M	0.5%	-27.5%	0.994%
8/11/2023	E Fund Management Co. Ltd.	33,708	$0.42M	0.0%	+33.8%	0.028%
8/11/2023	JPMorgan Chase & Co.	4,994,905	$62.74M	0.0%	+17.2%	4.090%
8/10/2023	MetLife Investment Management LLC	46,053	$0.58M	0.0%	+3.2%	0.038%
8/10/2023	ProShare Advisors LLC	19,611	$0.25M	0.0%	+6.4%	0.016%
8/10/2023	Profund Advisors LLC	113,113	$1.42M	0.1%	+37.4%	0.093%
8/10/2023	Mirae Asset Global Investments Co. Ltd.	61,193	$0.77M	0.0%	+7.7%	0.050%
8/10/2023	Citigroup Inc.	201,706	$2.53M	0.0%	-43.4%	0.166%
8/9/2023	TD Asset Management Inc	263,507	$3.31M	0.0%	+21.5%	0.217%
8/9/2023	Swiss National Bank	171,800	$2.16M	0.0%	+1.2%	0.141%

Data available starting January 2016

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $6.51

$6.35

$6.65

50 Day Range

MA: $7.73

$5.90

$10.32

52 Week Range

Now: $6.51

$5.70

$13.32

Volume

979,691 shs

Average Volume

1,137,390 shs

Market Capitalization

$864.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Who are the company insiders with the largest holdings of Relay Therapeutics?: Relay Therapeutics' top insider shareholders include:
Mark Murcko (Director)
Donald A Bergstrom (Insider)
Peter Rahmer (Insider)
Thomas Catinazzo (CFO)
Sanjiv Patel (CEO)
Brian Adams (Insider)
Andy Porter (Insider)
Learn More about top insider investors at Relay Therapeutics.
Who are the major institutional investors of Relay Therapeutics?: Relay Therapeutics' top institutional shareholders include:
Baillie Gifford & Co. — 0.27%
Susquehanna Portfolio Strategies LLC — 0.16%
Russell Investments Group Ltd. — 0.14%
Swiss National Bank — 0.12%
Congress Asset Management Co. MA — 0.11%
Mirae Asset Global Investments Co. Ltd. — 0.04%
Learn More about top institutional investors of Relay Therapeutics stock.
Which institutional investors are selling Relay Therapeutics stock?: Within the last quarter, RLAY stock was sold by these institutional investors:
Baillie Gifford & Co.
Principal Financial Group Inc.
Susquehanna Portfolio Strategies LLC
During the previous year, company insiders that have sold Relay Therapeutics company stock include:
Mark Murcko (Director)
Donald A Bergstrom (Insider)
Peter Rahmer (Insider)
Learn More investors selling Relay Therapeutics stock.
Which institutional investors are buying Relay Therapeutics stock?: Within the last quarter, RLAY stock was bought by institutional investors including:
Russell Investments Group Ltd.
Mesirow Financial Investment Management Inc.
Mesirow Financial Investment Management Inc.
Susquehanna Fundamental Investments LLC
China Universal Asset Management Co. Ltd.
Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC
Swiss National Bank